Skip to main navigation Skip to search Skip to main content

Correction to: Therapeutic drug monitoring of oral targeted antineoplastic drugs (European Journal of Clinical Pharmacology, (2021), 77, 4, (441-464), 10.1007/s00228-020-03014-8)

  • Anna Mueller-Schoell
  • , Stefanie L. Groenland
  • , Oliver Scherf-Clavel
  • , Madelé van Dyk
  • , Wilhelm Huisinga
  • , Robin Michelet
  • , Ulrich Jaehde
  • , Neeltje Steeghs
  • , Alwin D.R. Huitema
  • , Charlotte Kloft

Research output: Contribution to journalComment/debate

3 Citations (Scopus)

Abstract

Due to an error during production, some in-text and most of the in-table citations were not correctly displayed in the original previous online version of the article and have now been corrected. The original article has been corrected.

Original languageEnglish
Pages (from-to)465
Number of pages1
JournalEuropean Journal of Clinical Pharmacology
Volume77
Issue number4
Early online date15 Dec 2020
DOIs
Publication statusPublished - Apr 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Targeted antineoplastic drugs
  • Tyrosine kinase inhibitors
  • Therapeutic drug monitoring
  • Oral anticancer drugs
  • Personalised medicine

Fingerprint

Dive into the research topics of 'Correction to: Therapeutic drug monitoring of oral targeted antineoplastic drugs (European Journal of Clinical Pharmacology, (2021), 77, 4, (441-464), 10.1007/s00228-020-03014-8)'. Together they form a unique fingerprint.

Cite this